Jonathan Symonds Buys 1,550 Shares of GSK (LON:GSK) Stock

GSK plc (LON:GSK) insider Jonathan Symonds acquired 1,550 shares of GSK stock in a transaction dated Friday, June 19th. The shares were purchased at an average price of GBX 1,935 per share, for a total transaction of £29,992.50.

GSK Price Performance

LON:GSK traded up GBX 35.50 during mid-day trading on Tuesday, reaching GBX 1,960. The stock had a trading volume of 27,888,139 shares, compared to its average volume of 8,764,782. The stock has a market capitalization of £78.60 billion, a P/E ratio of 13.79, a P/E/G ratio of 1.24 and a beta of 0.29. The firm has a 50 day moving average price of GBX 1,955.63 and a two-hundred day moving average price of GBX 1,966.35. The company has a debt-to-equity ratio of 106.74, a quick ratio of 0.73 and a current ratio of 0.79. GSK plc has a one year low of GBX 1,288.61 and a one year high of GBX 2,282.

GSK (LON:GSK) last announced its quarterly earnings data on Wednesday, April 29th. The company reported GBX 46.50 earnings per share for the quarter. GSK had a net margin of 17.78% and a return on equity of 35.78%. The firm had revenue of GBX 762.90 billion during the quarter. As a group, analysts expect that GSK plc will post 175.980975 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on GSK shares. Citigroup reduced their price objective on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Jefferies Financial Group restated a “buy” rating and set a GBX 2,500 target price on shares of GSK in a report on Thursday, May 28th. Shore Capital Group restated a “buy” rating on shares of GSK in a research report on Wednesday, March 25th. Berenberg Bank reaffirmed a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a research note on Thursday, March 26th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a GBX 1,900 price objective on shares of GSK in a research report on Monday, June 8th. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, GSK presently has a consensus rating of “Hold” and an average price target of GBX 2,034.29.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.